Prostate Biopsy in the Case of PIRADS 5-Is Systematic Biopsy Mandatory?

Combining systematic biopsy (SB) with targeted biopsy (TB) in the case of a positive result from multiparametric magnetic resonance imaging (mpMRI) is a matter of debate. The Prostate Imaging Reporting and Data System (PIRADS) score of 5 indicates the highest probability of clinically significant prostate cancer (csPC) detection in TB. Potentially, omitting SB in the case of PIRADS 5 may have a marginal impact on the csPC detection rate. The aim of this study was to determine whether SB can be avoided in the case of PIRADS 5 and to identify potential factors allowing for performing TB only. This cohort study involved = 225 patients with PIRADS 5 on mpMRI (PIRADS 2.0/2.1) who underwent transperineal or transrectal combined biopsy (CB). CsPC was diagnosed in 51.6% ( = 116/225) of cases. TB and SB resulted in the detection of csPC in 48% ( = 108/225) and 20.4% ( = 46/225) of cases, respectively (TB vs. SB, < 0.001). When the TB was positive, SB detected csPC in = 38 of the cases (38/108 = 35%). SB added to TB significantly improved csPC detection in 6.9% of cases in absolute terms ( = 8/116) (TB vs. CB, = 0.008). The multivariate regression model proved that the significant predictors of csPC detection via SB were the densities of the prostate-specific antigen-PSAD > 0.17 ng/mL (OR = 4.038, 95%CI: 1.568-10.398); primary biopsy setting (OR = 2.818, 95%CI: 1.334-5.952); and abnormal digital rectal examination (DRE) (OR = 2.746, 95%CI: 1.328-5.678). In a primary biopsy setting ( = 103), SB detected 10% ( = 6/60) of the additional cases of csPC ( = 0.031), while in a repeat biopsy setting ( = 122), SB detected 3.5% ( = 2/56) of the additional cases of csPC ( = 0.5). In the case of PSAD > 0.17 ng/mL ( = 151), SB detected 7.4% ( = 7/95) of additional cases of csPC ( = 0.016), while in the case of PSAD < 0.17 ng/mL ( = 74), SB detected 4.8% ( = 1/21) of the additional cases of csPC ( = 1.0). The omission of SB had an impact on the csPC diagnosis rate in patients with PIRADS 5 score lesions. Patients who have already undergone prostate biopsy and those with low PSAD are at a lower risk of missing csPC when SB is avoided. However, performing TB only may result in missing other csPC foci located outside the index lesion, which can alter treatment decisions.